Zymeworks Unveils Promising Preclinical Data for Antibody-Drug Conjugates at EORTC-NCI-AACR Conference

Zymeworks Inc. (Nasdaq: ZYME), a pioneering biotechnology company, recently presented new preclinical data on its antibody-drug conjugate (ADC) candidates, ZW220 and ZW251, at the EORTC-NCI-AACR Conference in Barcelona. These ADCs, designed to tackle unmet needs in oncology, particularly for patients with hard-to-treat cancers, show promising results that could significantly impact cancer treatment options.

ZW220 targets NaPi2b-expressing cancers such as non-small cell lung cancer (NSCLC) and ovarian cancer. Preclinical findings indicate significant efficacy across various cancer models, outperforming previous NaPi2b-targeting ADCs. Its unique design features a topoisomerase I inhibitor payload, ZD06519, which shows effective internalization and cytotoxicity in tumor cells with low NaPi2b expression. Animal studies suggest that ZW220 can be administered at high doses, providing a better therapeutic index than other ADCs in the clinic.


ZW251 aims to address glypican-3 (GPC3) expressing hepatocellular carcinoma (HCC). Preclinical results demonstrated strong efficacy across various HCC models, even those with heterogeneous GPC3 expression. With a drug-antibody ratio designed for optimal efficacy and tolerability, ZW251 demonstrated significant safety in preclinical tests, suggesting its potential for use as either a standalone treatment or in combination with standard therapies.


Zymeworks is committed to developing multifaceted biotherapeutics and holds a robust pipeline of product candidates. Both ADCs represent exciting advancements in Zymeworks' mission to enhance cancer treatment options and improve patient outcomes. The company plans to submit IND applications for ZW220 in the first half of 2025 and ZW251 in the second half, marking significant milestones in their journey towards clinical trials.

As the market continues to evolve with the demand for innovative cancer therapies, Zymeworks stands out with its differentiated ADC strategy. These strategic positioning, combined with upcoming IND submissions and positive preclinical data, positions Zymeworks favorably for future growth and success in the biotechnology sector.